Cancer

01 November 2010

Sprycel Approval Expanded to Include Rare Leukemia

Drug believed to hinder proteins that encourage cancer growth

0

This article has not necessarily been edited by Health24.

THURSDAY, Oct. 28 (HealthDay News) -- Sprycel (dasatinib) has received an additional approval from the U.S. Food and Drug Administration to treat a rare form of blood cancer called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP -CML), the agency said Thursday in a news release.

CML is a slowly progressive disease of the blood and bone marrow that's believed related to a genetic abnormality, the FDA said.

Sprycel is among a class of drugs called oral kinase inhibitors, which are thought to inhibit certain proteins that foster growth of cancer cells. The drug was first approved in 2006 to treat other forms of CML that are resistant to standard therapies, including the Novartis anti-cancer drug Gleevec.

Sprycel's side effects could include decreased bone marrow activity, fluid retention, diarrhea, headache, muscle and bone pain, and rash.

Sprycel's maker, New York City-based Bristol-Myers Squibb, is required as a condition of approval to conduct ongoing clinical studies of the drug's long-term effectiveness for this condition, the FDA said.

More information

To learn more about CML, visit the U.S. National Library of Medicine.


(Copyright © 2010 HealthDay. All rights reserved.)

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules